Telephone: 225-763-3171; Fax: 225-763-0273
Article first published online: 19 APR 2011
Copyright © 2011 AlphaMed Press
Volume 29, Issue 5, pages 749–754, May 2011
How to Cite
Gimble, J. M., Bunnell, B. A., Chiu, E. S. and Guilak, F. (2011), Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation. STEM CELLS, 29: 749–754. doi: 10.1002/stem.629
Author contributions: J.M.G.: conception and design, financial support, administrative support, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; F.G., B.A.B., E.S.C.: conception and design, final approval of manuscript.
First published online in STEM CELLS EXPRESS March 23, 2011.
Disclosure of potential conflicts of interest is found at the end of this article.
- Issue published online: 19 APR 2011
- Article first published online: 19 APR 2011
- Accepted manuscript online: 23 MAR 2011 04:21PM EST
- Manuscript Accepted: 10 FEB 2011
- Manuscript Received: 5 JAN 2011
- Adult stem cells;
- Cellular therapy;
- Stem cell transplantation;
- Stromal cells;
- Clinical translation;
- Current Good Manufacturing Practices
Subcutaneous fat has emerged as an alternative tissue source for stromal/stem cells in regenerative medicine. Over the past decade, international research efforts have established a wealth of basic science and preclinical evidence regarding the differentiation potential and regenerative properties of both freshly processed, heterogeneous stromal vascular fraction cells and culture expanded, relatively homogeneous adipose-derived stromal/stem cells. The stage has been set for clinicians to translate adipose-derived cells from the bench to the bedside; however, this process will involve “development” steps that fall outside of traditional “hypothesis-driven, mechanism-based” paradigm. This concise review examines the next stages of the development process for therapeutic applications of adipose-derived cells and highlights the current state of the art regarding clinical trials. It is recommended that the experiments addressing these issues be reported comprehensively in the peer-review literature. This transparency will accelerate the standardization and reproducibility of adipose-derived cell therapies with respect to their efficacy and safety. STEM CELLS 2011;29:749–754